Summary & Overview
CPT 69100: Biopsy of the External Ear
CPT code 69100 is a nationally recognized billing code for the biopsy of the external ear, a procedure performed by otolaryngologists, dermatologists, and family medicine physicians. This code is used to document and bill for the collection of tissue samples from the external ear, which are critical for diagnosing a variety of conditions, including infections, benign growths, and malignancies. The procedure is most often conducted in an office setting, making it accessible for routine evaluation and early intervention.
Major payers covering this service include Aetna, Blue Cross Blue Shield, Cigna Health, Medicare, and UnitedHealthcare. The publication provides an overview of payer coverage, clinical indications, and related billing codes, offering readers insight into national benchmarks and policy updates relevant to 69100. Key topics include the clinical context for external ear biopsies, common diagnoses associated with the procedure, and how it fits within broader otolaryngology and dermatology practices. Readers will gain a comprehensive understanding of the procedural, billing, and policy landscape for 69100, including its relationship to other ear and skin procedures.
CPT Code Overview
CPT code 69100 represents a biopsy of the external ear, a procedure commonly performed in the field of otolaryngology. This service is typically provided in an office setting (Place of Service 11), where clinicians obtain tissue samples from the external ear for diagnostic evaluation. The procedure is essential for identifying a range of ear conditions, including benign and malignant lesions, and supports accurate clinical decision-making. Biopsies of the external ear are a routine part of otolaryngology practice, contributing to the early detection and management of ear diseases.
Clinical & Coding Specifications
Clinical Context
A patient presents to the office with a visible lesion or abnormality on the external ear. The provider, typically an otolaryngologist, dermatologist, or family medicine physician, evaluates the area and determines that a biopsy is necessary to rule out benign or malignant neoplasms, or to further investigate persistent symptoms such as chronic otitis externa or unexplained masses. The procedure is performed in the office setting (Place of Service 11), where a small tissue sample is taken from the external ear for pathological examination. The workflow includes pre-procedure assessment, local anesthesia, biopsy, specimen handling, and post-procedure instructions.
Coding Specifications
-
Modifiers:
LT: Indicates the procedure was performed on the left side.RT: Indicates the procedure was performed on the right side.
-
Provider Taxonomies:
| Taxonomy Code | Specialty |
|---|---|
207Y00000X | Otolaryngologist |
207N00000X | Dermatologist |
207Q00000X | Family Medicine Physician |
- Specialty Representation:
- Otolaryngologists perform biopsies for ear-related conditions.
- Dermatologists address skin lesions of the external ear.
- Family medicine physicians may perform biopsies in primary care settings.
Related Diagnoses
-
H61.20: Impacted cerumen, unspecified ear- Relevant when earwax obstructs the external ear, potentially requiring biopsy if underlying pathology is suspected.
-
H60.90: Otitis externa, unspecified ear- Chronic or atypical external ear infections may necessitate biopsy to rule out neoplastic or other causes.
-
D23.20: Other benign neoplasm of skin of ear and external auricular canal- Biopsy is performed to confirm benign nature of a lesion on the external ear.
-
C44.201: Unspecified malignant neoplasm of skin of right ear and external auricular canal- Biopsy is essential for diagnosis and management of suspected malignant lesions on the right external ear.
-
C44.202: Unspecified malignant neoplasm of skin of left ear and external auricular canal- Biopsy is essential for diagnosis and management of suspected malignant lesions on the left external ear.
Related CPT Codes
-
69210: Removal impacted cerumen requiring instrumentation, unilateral- Used when impacted earwax is removed with instruments. May be performed before or after a biopsy if cerumen obstructs the area.
-
69200: Removal foreign body from external auditory canal; without general anesthesia- Used for removal of foreign objects from the ear canal. Sometimes necessary prior to biopsy if a foreign body is present.
-
69105: Excision external ear lesion- Used for complete excision of a lesion on the external ear. May be an alternative to
69100if the lesion is removed entirely rather than biopsied.
- Used for complete excision of a lesion on the external ear. May be an alternative to
-
11102: Tangential biopsy of skin; single lesion- Used for skin biopsies, including those on the external ear. May be used as an alternative or in conjunction with
69100depending on lesion characteristics.
- Used for skin biopsies, including those on the external ear. May be used as an alternative or in conjunction with
-
Commonly Used Together or as Alternatives:
69100and69105are alternatives depending on whether a biopsy or excision is performed.69210and69200may be performed prior to69100if cerumen or foreign bodies need to be removed for access.11102may be used for skin lesions when a tangential biopsy is appropriate.
National Reimbursement Benchmarks
Nationally, the mean rate for CPT code 69100 is $96.06 for Medicare, while the average commercial benchmark (BUCA) is higher at $103.83. Among individual commercial payers, UnitedHealth Group and Cigna report the highest mean rates at $139.88 and $136.58, respectively, with Aetna at the lower end at $79.33.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies significantly across payers. Medicare shows the tightest range ($10.00), indicating relatively consistent reimbursement rates. In contrast, Cigna and UnitedHealth Group exhibit the widest dispersions ($79.00 and $75.00, respectively), reflecting greater variability in commercial payments.
The table and chart below present a detailed breakdown of national payer benchmarks for CPT code 69100, including mean rates and percentile values.
State Benchmarks
State: AK1 / 50
Alaska Benchmarks
Alaska's reimbursement rates for CPT code 69100 show substantial variation across payers, with the highest mean rate from Aetna at $293.69 and the lowest from Medicare at $92.82. The rate spread, calculated as the difference between the 75th and 25th percentiles, is most pronounced for Cigna ($125.25), indicating significant variability in Cigna's payments. In contrast, Aetna's percentiles are identical, suggesting uniformity in its rates across providers.
Compared to national averages, Alaska's commercial payers consistently offer higher reimbursement rates, with Aetna's mean rate nearly four times the national mean. The table and chart below present the full breakdown of payer-specific rates and percentiles for Alaska, highlighting the state's elevated payment landscape for this procedure.
Key Insights for Alaska
- Aetna is the highest paying payer in Alaska for CPT 69100, with a mean rate of $293.69, while Medicare is the lowest at $92.82.
- All commercial payers in Alaska reimburse at rates significantly above their respective national averages, with Aetna's mean rate nearly four times the national mean.
- The rate spread is widest for Aetna (P75-P25 = $0, due to identical percentiles), while Cigna shows the largest spread ($125.25), indicating greater variability in Cigna's reimbursement rates.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.